Clinical Trial

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
GEMINI-PeriOp GC study will assess the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of novel agents or novel combinations as perioperative treatment in participants with locally advanced resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma who have not received previous treatment for the disease.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2025-07-07; most recent amendment 2026-07-09.
Status change: Not Yet Recruiting → Recruiting 2025-07-29
Trial Details
NCT Number NCT07069712
Lead Sponsor AstraZeneca
Collaborators: Parexel
Conditions Gastroesophageal Adenocarcinoma
Enrollment 100 participants
Start Date 2025-07-17
Primary Completion 2027-01-28 (estimated)
Study Completion 2028-09-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-10